Octreotide Impurity 6 is a structural variant formed during octreotide synthesis or oxidative stress. Subtle changes in residue composition or side-chain protection influence disulfide connectivity and folding. Researchers use it as a reference for impurity quantification and chromatographic validation. Applications include peptide stability studies, process monitoring, and structural analysis.
CAT No: R2762
CAS No:191806-77-6
Synonyms/Alias:(4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-19-amino-10-(4-aminobutyl)-16-benzyl-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxylic acid
Octreotide Impurity 6 is a synthetic peptide derivative structurally related to octreotide, a well-known somatostatin analog. As an impurity reference standard, it plays a critical role in the analytical characterization and quality assessment of peptide-based pharmaceuticals. Its defined molecular structure enables researchers to accurately identify and quantify related substances during the production and development of octreotide formulations. The presence and profile of such impurities are of significant interest in peptide chemistry, regulatory science, and pharmaceutical quality control, making Octreotide Impurity 6 an essential tool for laboratories engaged in peptide drug development and manufacturing.
Analytical method development: In the context of pharmaceutical analysis, Octreotide Impurity 6 is routinely used for the optimization and validation of chromatographic methods such as HPLC or LC-MS. Its inclusion as a reference standard allows analytical scientists to establish method sensitivity, specificity, and linearity for impurity profiling. By providing a benchmark for retention time and spectral data, this compound assists in ensuring that analytical methods can reliably distinguish between the active pharmaceutical ingredient and structurally similar impurities, thereby enhancing confidence in the integrity of impurity testing protocols.
Quality control and batch release: The precise quantification of Octreotide Impurity 6 is integral to the quality control processes within peptide manufacturing. Its use enables the detection and monitoring of trace-level impurities that may arise during synthesis, purification, or storage of octreotide and related peptides. By incorporating this impurity standard into routine QC assays, manufacturers can verify that impurity levels remain within acceptable thresholds, supporting the consistent production of high-quality peptide drug substances and intermediates.
Peptide impurity profiling: Comprehensive impurity profiling is fundamental to understanding the chemical stability and degradation pathways of peptide therapeutics. Octreotide Impurity 6 serves as a key marker for identifying and quantifying specific byproducts that may form under various stress conditions, such as exposure to heat, light, or oxidizing agents. Its use in forced degradation studies and stability-indicating assays provides valuable insights into the robustness of peptide formulations and informs the development of strategies to mitigate impurity formation.
Process development and optimization: During the scale-up and optimization of peptide synthesis, the formation of specific impurities such as this one can reveal critical information about reaction pathways and process efficiency. Monitoring the levels of Octreotide Impurity 6 throughout different stages of synthesis enables process chemists to fine-tune reaction conditions, purification steps, and storage protocols. Such data-driven process improvements contribute to higher yields, better reproducibility, and reduced risk of unwanted byproduct accumulation.
Regulatory submission support: Accurate identification and quantification of peptide impurities are essential components of regulatory documentation for new drug applications and product lifecycle management. Reference standards like Octreotide Impurity 6 play a pivotal role in compiling comprehensive impurity profiles required by regulatory agencies. Their use facilitates transparent reporting of impurity content, supports risk assessments, and underpins the scientific justification for proposed impurity limits, ultimately contributing to the regulatory acceptance of peptide-based pharmaceuticals.
1. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
5. The spatiotemporal control of signalling and trafficking of the GLP-1R
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More